3Sem.·

BridgeBio shares rise 25% after FDA approval of Attruby. $BBIO (+0,47 %)


The company is currently seeking marketing authorization for Attruby. DAX-listed Bayer is also likely to be keeping a close eye on the approval process. The Leverkusen-based company secured the exclusive marketing rights to Acoramidis for the European market in March for 310 million dollars in the form of an upfront payment and short-term milestone payments. $BAYN (+0,17 %)


BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares rose 25% after the company received approval from the U.S. Food and Drug Administration (FDA) for Attruby™ (Acoramidis). Attruby is an oral medication for the treatment of adults with ATTR-CM that aims to reduce cardiovascular deaths and hospitalizations. The approval is based on the positive results of the ATTRibute-CM Phase 3 trial.


https://de.investing.com/news/stock-market-news/bridgebioaktien-steigen-um-25-nach-fdazulassung-von-attruby-93CH-2791044


https://www.deraktionaer.de/artikel/pharma-biotech/bayer-partner-bridgebio-pharma-zulassung-aktie-vor-kurssprung-20370523.html#google_vignette

previw image
8
Participez à la conversation